Antonia S, et al. Overall survival with durvalumab versus placebo after chemoradiotherapy in stage III NSCLC: updated results from PACIFIC. IASLC 2018, abstract PL02.01.
25ste Nationale Longkanker Symposium
feb 2024 | Chirurgie, Immuuntherapie, Longoncologie, Radiotherapie